These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15727487)

  • 1. Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.
    Claudio JO; Stewart AK
    Am J Pharmacogenomics; 2005; 5(1):35-43. PubMed ID: 15727487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling and multiple myeloma.
    Shaughnessy J; Zhan F; Barlogie B; Stewart AK
    Best Pract Res Clin Haematol; 2005; 18(4):537-52. PubMed ID: 16026736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights from the gene expression profiling of multiple myeloma.
    Claudio JO; Masih-Khan E; Stewart AK
    Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigative tools for diagnosis and management.
    Munshi NC
    Hematology Am Soc Hematol Educ Program; 2008; ():298-305. PubMed ID: 19074100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.
    Agnelli L; Tassone P; Neri A
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S55-68. PubMed ID: 23614397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomics in multiple myeloma: biology and clinical implications.
    Chng WJ; Fonseca R
    Pharmacogenomics; 2005 Sep; 6(6):563-73. PubMed ID: 16142997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
    Stewart AK; Fonseca R
    J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.
    Amodio N; Di Martino MT; Neri A; Tagliaferri P; Tassone P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S125-37. PubMed ID: 23692413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review).
    Martino A; Sainz J; Buda G; Jamroziak K; Reis RM; García-Sanz R; Jurado M; Ríos R; Szemraj-Rogucka Z; Marques H; Lesueur F; Moreno V; Orciuolo E; Gemignani F; Landi S; Rossi AM; Dumontet C; Petrini M; Campa D; Canzian F
    Int J Oncol; 2012 Mar; 40(3):625-38. PubMed ID: 22159523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.
    Zanwar S; Kumar S
    Leuk Lymphoma; 2021 Dec; 62(13):3087-3097. PubMed ID: 34304677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance and contribution to the diagnosis of multiple myeloma according to the IGF1-R gene expression profile].
    Safra I; Rezgui I; Ladeb S; Skouri N; Ben Amor A; Lakhal A; Torjemane L; Ben Othman T; Ben Ahmed M
    Arch Inst Pasteur Tunis; 2013; 90(1-4):61-7. PubMed ID: 26012212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
    Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
    Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and risk stratification in multiple myeloma.
    van de Donk NW; Sonneveld P
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):791-813. PubMed ID: 25212883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
    Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
    Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
    Chan NC; Chan NP
    Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for multiple myeloma in the era of novel agents.
    Bladé J; Rosiñol L; Cibeira MT
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii117-20. PubMed ID: 18790932
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
    Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.